#USA #EpiVax #Rhode Island #ISPRI #JanusMatrix

EpiVax Introduces AI-Optimized Models for Immunogenicity Prediction

In a groundbreaking move, EpiVax, Inc. has launched enhanced AI-driven features for their proprietary platform, ISPRI™. This innovative in-silico technology is designed to assess the immunogenicity risk associated with biotherapeutics. The updates include the JanusMatrix™ 2.1 model, a refined tolerance-adjusted immunogenicity score, and an updated prediction model for Anti-Drug Antibodies (ADA). The primary aim of these enhancements is to provide deeper insights into immunogenicity risks.

For over two decades, EpiVax has been at the forefront of computational immunology, developing advanced in-silico algorithms to evaluate the risks posed by biotherapeutic sequences. Key components of this research are EpiMatrix® and JanusMatrix™, which assess the presence of T-cell epitopes and conservation across human species. This evaluation helps characterize immunogenicity risks derived from sequence data and immune tolerance. ISPRI™ brings these tools together with other thoroughly validated methods for risk assessment of candidate and contaminant sequences.

New Features of JanusMatrix™ 2.1

The latest iteration, JanusMatrix™ 2.1, leverages AI to enhance the prediction of immune tolerance. It achieves this by weighting the cross-conservation of human epitopes based on expression and prevalence data. With this refinement, the platform can provide a more precise characterization of therapeutic epitopes and their tolerance profiles.

Another significant addition is the JanusMatrix-adjusted EpiMatrix Score, which integrates tolerance potential directly into EpiMatrix scores, thereby delivering insights into intrinsic effector-epitope density. This allows for a more biologically valid assessment of immunogenicity risks across various therapeutic modalities.

Updates to ADA 2.2 Model

Alongside these improvements, EpiVax has also released an updated version of its ADA prediction model, ADA 2.2. This enhanced model synergizes epitope-based metrics with biophysical properties and mechanism-of-action criteria to provide an additional avenue for assessing the immunogenicity risk of antibodies. It's specifically trained utilizing a diverse array of clinical monoclonal antibodies, which strengthens the correlation between predicted immunogenicity and clinically observed outcomes. Moreover, it offers an added layer of confidence in risk interpretation alongside the JAX score.

This latest release not only bolsters EpiVax’s industry-leading immunoinformatics capabilities but also heightens the relevance and predictive power of in-silico risk assessments for immunogenicity. These enhancements align closely with recent FDA initiatives aimed at promoting the adoption of human-relevant New Approach Methodologies (NAMs), while simultaneously aiding sponsors in identifying immunological risks, safeguarding the value of their assets, and facilitating lower-risk development programs.

About EpiVax

EpiVax collaborates with biopharmaceutical developers to manage immunogenicity risk throughout the entire product lifecycle. By employing rigorous scientific expertise in applying cutting-edge in-silico analyses and in-vitro methodologies, insights derived from actionable data allow partners to minimize uncertainties, mitigate risks, and allocate resources more efficiently. Concurrently, these efforts help develop regulatory-compliant strategies leading to safer and more effective therapies.

For more information, media inquiries can be directed to Sarah Moniz, Head of Business Development and Marketing at [email protected]